Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by CalciMedica, Inc. on August 19, 2026. The filing details the outcomes of eight proposals voted on by stockholders, including director elections, executive compensation, equity plan amendments, and capital structure changes.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity actions; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Voting Results
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the authorized share reserve by 7,500,000 shares and modifying the automatic annual increase calculation to include shares from convertible preferred stock and pre-funded warrants.
- Reverse Stock Split Authorization: Stockholders approved a reverse stock split with a ratio between 1-for-2 and 1-for-10, along with a proportional reduction in authorized shares. The specific ratio and timing remain at the Board's discretion.
- Equity Issuance Approvals: Stockholders approved the issuance of Series A and Series B Warrants (Common Warrants) to purchase up to 18,673,429 shares under Nasdaq Listing Rule 5635(d). Additionally, approval was granted for the issuance of warrants to purchase up to 1,680,565 shares to directors and officers under Nasdaq Listing Rule 5635(c).
- Director Elections: Allan Shaw and Robert N. Wilson were elected as Class III directors for three-year terms.
- Accounting Firm: Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: The advisory vote on executive compensation was approved. Stockholders indicated a preference for annual say-on-pay votes.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance or management commentary on operational outlook. The primary risk highlighted is the potential dilution from the approved warrant issuances and the uncertainty regarding the timing and specific ratio of the authorized reverse stock split. The Board has determined to hold future say-on-pay votes annually until at least the 2032 Annual Meeting.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once determined by the Board.
- Review the definitive proxy statement (Schedule 14A) filed on July 23, 2026, for full details on the amended 2023 Equity Incentive Plan.
- Monitor the exercise terms and potential dilution impact of the 18,673,429 Common Warrants and the 1,680,565 warrants issued to directors and officers.
- Confirm the impact of the warrant issuances on the company's capitalization table and Nasdaq listing compliance.